End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.28 CNY | -3.15% | -4.44% | -33.01% |
May. 27 | Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug | MT |
May. 20 | Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves the Cash Dividend for the Year 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an expected P/E ratio at 33.88 and 25.06 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-33.01% | 1.44B | - | ||
+20.39% | 43.67B | B- | ||
+26.21% | 22.79B | B+ | ||
+21.43% | 15.45B | - | ||
+18.82% | 14.29B | B+ | ||
+53.37% | 12.83B | B | ||
-0.05% | 6.79B | - | - | |
-11.88% | 6.52B | B+ | ||
-8.87% | 5.73B | - | - | |
+12.62% | 5.59B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 002675 Stock
- Ratings Yantai Dongcheng Pharmaceutical Group Co.,Ltd.